Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
Faculty of Paramedical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Int Immunopharmacol. 2022 Jun;107:108655. doi: 10.1016/j.intimp.2022.108655. Epub 2022 Feb 25.
Multiple efforts are currently underway to control and treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19) worldwide. Despite all efforts, the virus that emerged in Wuhan city has rapidly spread globally and led to a public health emergency of international concern (PHEIC) due to the lack of approved antiviral therapy. Nevertheless, SARS-CoV-2 has had a significant influence on the evolution of cellular therapeutic approaches. Adoptive immune cell therapy is innovative and offers either promising prophylactic or therapy for patients with moderate-to-severe COVID-19. This approach is aimed at developing safety and providing secure and effective therapy in combination with standard therapy for all COVID-19 infected individuals. Based on the effective results of previous studies on both inflammatory and autoimmune diseases, various immune cell therapies against COVID-19 have been reviewed and discussed. It must be considered that the application of cell therapy for treatment and to eliminate infected respiratory cells could result in excessive inflammation, so this treatment must be used in combination with other treatments, despite its many beneficial efforts.
目前，全球正在多方面努力控制和治疗严重急性呼吸综合征冠状病毒 2（SARS-CoV-2），引发 2019 冠状病毒病（COVID-19）。尽管付出了所有努力，但在武汉出现的这种病毒已经迅速在全球范围内传播，并因缺乏批准的抗病毒疗法而导致国际关注的突发公共卫生事件（PHEIC）。然而，SARS-CoV-2 对细胞治疗方法的发展产生了重大影响。过继免疫细胞疗法具有创新性，为中重度 COVID-19 患者提供了有希望的预防或治疗选择。这种方法旨在结合标准疗法为所有 COVID-19 感染者开发安全性，并提供安全有效的治疗。基于以前在炎症和自身免疫性疾病方面的研究的有效结果，对针对 COVID-19 的各种免疫细胞疗法进行了回顾和讨论。必须考虑到，细胞疗法用于治疗和消除感染呼吸道细胞可能会导致过度炎症，因此这种治疗必须与其他治疗方法联合使用，尽管它有许多有益的作用。
